CN119638681A - 三嗪二酮类衍生物、其制备方法及其在医药上的应用 - Google Patents
三嗪二酮类衍生物、其制备方法及其在医药上的应用 Download PDFInfo
- Publication number
- CN119638681A CN119638681A CN202411649375.0A CN202411649375A CN119638681A CN 119638681 A CN119638681 A CN 119638681A CN 202411649375 A CN202411649375 A CN 202411649375A CN 119638681 A CN119638681 A CN 119638681A
- Authority
- CN
- China
- Prior art keywords
- group
- alkyl
- membered
- cycloalkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
- C07D251/40—Nitrogen atoms
- C07D251/42—One nitrogen atom
- C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011310827 | 2020-11-20 | ||
| CN2020113108274 | 2020-11-20 | ||
| CN2021100215094 | 2021-01-08 | ||
| CN202110021509 | 2021-01-08 | ||
| CN202110244090 | 2021-03-05 | ||
| CN2021102440909 | 2021-03-05 | ||
| CN2021104643753 | 2021-04-28 | ||
| CN202110464375 | 2021-04-28 | ||
| CN202180065655.5A CN116323598B (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| PCT/CN2021/131642 WO2022105852A1 (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180065655.5A Division CN116323598B (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119638681A true CN119638681A (zh) | 2025-03-18 |
Family
ID=81708401
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411649375.0A Pending CN119638681A (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN202180065655.5A Active CN116323598B (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN202411649482.3A Pending CN119638682A (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN202411649280.9A Pending CN119638680A (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180065655.5A Active CN116323598B (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN202411649482.3A Pending CN119638682A (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
| CN202411649280.9A Pending CN119638680A (zh) | 2020-11-20 | 2021-11-19 | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240010639A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4249474A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7849587B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230110538A (cg-RX-API-DMAC7.html) |
| CN (4) | CN119638681A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021381664B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198934A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023005533A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202227420A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022105852A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| IL325304A (en) * | 2018-10-29 | 2026-02-01 | Myokardia Inc | 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione |
| KR20240015622A (ko) | 2021-03-04 | 2024-02-05 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| TW202302541A (zh) * | 2021-03-17 | 2023-01-16 | 美商翰森生物有限責任公司 | 含氮雜環酮、其製備方法和醫藥用途 |
| EP4370116B1 (en) | 2021-07-16 | 2025-01-15 | Cytokinetics, Inc. | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy |
| CN117088854A (zh) * | 2022-05-20 | 2023-11-21 | 江苏恒瑞医药股份有限公司 | 一种三嗪二酮类衍生物的可药用盐、晶型及制备方法 |
| WO2023222103A1 (zh) | 2022-05-20 | 2023-11-23 | 江苏恒瑞医药股份有限公司 | 一种三嗪二酮类衍生物的晶型及制备方法 |
| WO2024056096A1 (zh) * | 2022-09-16 | 2024-03-21 | 江苏豪森药业集团有限公司 | 一种含氮杂环酮化合物的晶型及其制备方法 |
| WO2026130464A1 (zh) * | 2024-12-18 | 2026-06-25 | 江苏恒瑞医药股份有限公司 | 制备治疗肥厚型心肌病药物的用途 |
| WO2026153470A1 (zh) * | 2025-01-16 | 2026-07-23 | 江苏恒瑞医药股份有限公司 | 制备治疗非梗阻性肥厚型心肌病药物的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5502089B2 (ja) * | 2008-10-09 | 2014-05-28 | エフ.ホフマン−ラ ロシュ アーゲー | アミロイドβのモジュレーター |
| SG173647A1 (en) * | 2009-02-13 | 2011-10-28 | Shionogi & Co | Novel triazine derivative and pharmaceutical composition containing same |
| US20110319400A1 (en) * | 2010-06-28 | 2011-12-29 | Flores Christopher M | Prokineticin 1 receptor antagonists for the treatment of pain |
| US9718790B2 (en) * | 2010-08-10 | 2017-08-01 | Shionogi & Co., Ltd. | Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| US9663516B2 (en) * | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| JP7042812B2 (ja) | 2016-06-20 | 2022-03-28 | ノバルティス アーゲー | トリアゾロピリミジン化合物の結晶形態 |
| JP7412328B2 (ja) | 2017-07-24 | 2024-01-12 | ノバルティス アーゲー | Nlrp活性に関連する状態を治療するための化合物及び組成物 |
| IL322175A (en) | 2017-08-04 | 2025-09-01 | Myokardia Inc | Treatment of hypertrophic cardiomyopathy (HCM) with pyrimidinedione compounds |
| CN111094300B (zh) * | 2018-01-31 | 2022-09-16 | 江苏恒瑞医药股份有限公司 | 苯并杂芳基类衍生物、其制备方法及其在医药上的应用 |
| MA53491A (fr) * | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| IL325304A (en) | 2018-10-29 | 2026-02-01 | Myokardia Inc | 4-Tetrahydropyran-4-yl-6-fluoro-7-phenyl-8,7,6,5-tetrahydro-h1-pyrido[3,2-d]pyrimidine-2,4-dione |
| WO2020151605A1 (zh) * | 2019-01-25 | 2020-07-30 | 青岛吉澳医药科技有限公司 | 氘代苯甲氨嘧啶二酮衍生物及其用途 |
| CN110698415B (zh) | 2019-10-21 | 2023-05-09 | 上海先行医药开发有限公司 | 一种肌球蛋白抑制剂及其制备方法和用途 |
| TW202302541A (zh) * | 2021-03-17 | 2023-01-16 | 美商翰森生物有限責任公司 | 含氮雜環酮、其製備方法和醫藥用途 |
-
2021
- 2021-11-19 EP EP21893999.9A patent/EP4249474A4/en active Pending
- 2021-11-19 AU AU2021381664A patent/AU2021381664B2/en active Active
- 2021-11-19 CA CA3198934A patent/CA3198934A1/en active Pending
- 2021-11-19 CN CN202411649375.0A patent/CN119638681A/zh active Pending
- 2021-11-19 WO PCT/CN2021/131642 patent/WO2022105852A1/zh not_active Ceased
- 2021-11-19 KR KR1020237019549A patent/KR20230110538A/ko active Pending
- 2021-11-19 JP JP2023530323A patent/JP7849587B2/ja active Active
- 2021-11-19 CN CN202180065655.5A patent/CN116323598B/zh active Active
- 2021-11-19 CN CN202411649482.3A patent/CN119638682A/zh active Pending
- 2021-11-19 TW TW110143208A patent/TW202227420A/zh unknown
- 2021-11-19 US US18/253,704 patent/US20240010639A1/en active Pending
- 2021-11-19 MX MX2023005533A patent/MX2023005533A/es unknown
- 2021-11-19 CN CN202411649280.9A patent/CN119638680A/zh active Pending
-
2026
- 2026-02-12 JP JP2026021203A patent/JP2026097848A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3198934A1 (en) | 2022-05-27 |
| AU2021381664A1 (en) | 2023-06-15 |
| JP2023550444A (ja) | 2023-12-01 |
| KR20230110538A (ko) | 2023-07-24 |
| CN116323598B (zh) | 2024-11-15 |
| CN119638680A (zh) | 2025-03-18 |
| EP4249474A4 (en) | 2024-04-17 |
| CN119638682A (zh) | 2025-03-18 |
| EP4249474A1 (en) | 2023-09-27 |
| WO2022105852A1 (zh) | 2022-05-27 |
| CN116323598A (zh) | 2023-06-23 |
| US20240010639A1 (en) | 2024-01-11 |
| AU2021381664B2 (en) | 2026-05-28 |
| JP2026097848A (ja) | 2026-06-16 |
| JP7849587B2 (ja) | 2026-04-22 |
| TW202227420A (zh) | 2022-07-16 |
| MX2023005533A (es) | 2023-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116323598B (zh) | 三嗪二酮类衍生物、其制备方法及其在医药上的应用 | |
| CN116507621B (zh) | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| CN114539229B (zh) | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| CN114516843B (zh) | 嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| WO2022007979A1 (zh) | 稠合咪唑类衍生物、其制备方法及其在医药上的应用 | |
| CN114149423B (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| US10442794B2 (en) | Processes for preparing pyridine carboxamide derivatives | |
| TW202321263A (zh) | 磺醯胺衍生物、其製備方法及其在醫藥上的應用 | |
| CN107033097B (zh) | 噁二唑类衍生物、其制备方法及其在医药上的应用 | |
| CN114456163B (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
| CN114539257B (zh) | 嘧啶二酮类螺环衍生物、其制备方法及其在医药上的应用 | |
| EP4273150A1 (en) | Tricyclic compound, and preparation method therefor and medical use thereof | |
| KR101739362B1 (ko) | 1,2 나프토퀴논 유도체 및 이의 제조방법 | |
| CN112996783A (zh) | 2-氨基嘧啶类衍生物、其制备方法及其在医药上的应用 | |
| HK40095559A (en) | Triazine dione derivative, preparation method therefor and application thereof in medicine | |
| HK40095559B (en) | Triazine dione derivative, preparation method therefor and application thereof in medicine | |
| EA048346B1 (ru) | Производное триазиндионов, способ его получения и его применение в медицине | |
| CA3203698A1 (en) | 2-pyridone derivative, and preparation method therefor and pharmaceutical application thereof | |
| CN119039236A (zh) | 一种苄胺嘧啶二酮衍生物及其用途 | |
| WO2025193111A1 (en) | An imidazole-indole derivative binding to 5-ht7 serotonin receptor, a pharmaceutical composition comprising the derivative, uses of the derivative and the composition, and an intermediate product for manufacturing the imidazole-indole derivative | |
| CN115884776A (zh) | 杂环大环化合物及其医药用途 | |
| CN114907406A (zh) | 嘧啶衍生物、其制备方法及其在医药上的应用 | |
| HK1227869B (en) | Pyridinecarboxamide derivatives, preparation method therefor and pharmaceutical uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |